Friedl-Naderer Johanna, CCO, reported an open-market or private sale at Dyne Therapeutics, Inc. involving 185.000000 shares for an estimated $3492.80. Reported holdings after the transaction were 152897.000000 shares. The stored filing text includes a detected 10b5-1 reference.
Stored Form 4 columns with their raw values
Badges describe filing facts only — not predictions.
Compact filing score computed from stored Form 4 facts. Version v1.
This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.
Form 4 relationship flags and nearby filing context
Chief Commercial Officer
Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on Septembe…
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $24.29 to $24.50, inclusive. The Reporting Person undertakes t…
Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December…
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $18.77 to $18.92, inclusive. The Reporting Person undertakes t…
Includes 102,966 unvested RSUs.
0 other filings
0 recent txs